Thymulin
Also known as: FTS · facteur thymique sérique · zinc-thymulin
A zinc-bound nonapeptide thymic hormone with distinctive research applications spanning immune-cognitive research, sickness-behaviour research, and neuroinflammation-mediated cognitive-decline contexts.
Thymulin (FTS) is a zinc-bound nonapeptide thymic hormone with distinctive immune-cognitive research applications spanning sickness-behaviour and neuroinflammation contexts.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Neuroprotection
- Half-life
- Short plasma half-life; sustained pharmacodynamic effects on immune tone
Section 1
Overview
Thymulin (also known as FTS, from the French facteur thymique sérique) is a nonapeptide thymic hormone that requires zinc-binding for biological activity — its zinc-bound form is the pharmacologically active species. It was originally identified in the 1970s as the thymic peptide responsible for T-cell maturation effects, and has since been characterised for a range of immunomodulatory, neuroendocrine, and cognitive-relevance research applications.
The compound's cognitive-relevance research context emerges from the immune-cognitive research field. Immune-system-mediated cognitive effects — the 'sickness behaviour' framework, cytokine-mediated cognitive decline, and inflammaging-mediated cognitive-ageing contributions — are all research contexts where an immunomodulatory peptide with CNS effects provides research-tool relevance. Thymulin's distinctive zinc-dependence adds a research-tool angle for probing zinc-immune-cognitive interactions specifically.
Direct current research use of thymulin is specialised rather than mainstream. The compound retains research-tool relevance for immune-cognitive research applications and provides completion of the thymic-peptide-family coverage on this reference alongside the more widely-used Thymalin preparation.
Section 2
Discovery & History
- Identified in the 1970s by Bach and colleagues as the thymic serum factor responsible for T-cell maturation effects.
- The zinc-binding requirement for biological activity was characterised subsequently, distinguishing thymulin from other thymic peptide preparations.
- Extensively characterised through the 1980s and 1990s for immunomodulatory effects across multiple experimental models.
- Research applications extended into neuroinflammation, sickness-behaviour, and immune-cognitive research contexts through the 2000s and 2010s.
- No entry for Thymulin was found in the electronic medicines compendium (emc) on 17 October 2026.
Section 3
Mechanism of Action
- 1Zinc-dependent binding to thymulin receptors on T-cell and other immune-cell populations, mediating T-cell maturation and immunomodulatory effects.
- 2Modulation of pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) via effects on macrophage and lymphocyte activation state.
- 3Anti-inflammatory effects in preclinical models of inflammatory disease, providing the mechanistic scaffold for the immune-cognitive research applications.
- 4Reported effects on sickness-behaviour phenotype in preclinical models — reduced cytokine-mediated cognitive and behavioural effects in lipopolysaccharide-driven sickness models.
- 5Effects on the hypothalamic-pituitary-adrenal (HPA) axis via central immune-endocrine interactions.
- 6Modulation of microglial activation and neuroinflammation in preclinical CNS-injury and neurodegenerative disease models.
- 7Reported effects on cognitive endpoints in aged and immunocompromised research populations, extending the immune-cognitive research application angle.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Distinctive zinc-dependent immunomodulatory mechanism providing a research-tool niche unshared by other peptides on this reference.
- 2Immune-cognitive research applications relevant to inflammaging and neuroinflammation-mediated cognitive decline research.
- 3Sickness-behaviour research applications providing a specific research-tool angle for probing cytokine-mediated cognitive effects.
- 4Substantial preclinical characterisation across immunomodulatory, neuroendocrine, and cognitive contexts.
- 5Well-characterised acute-safety profile from decades of academic research use.
- 6Zinc-dependence adds a research-tool angle for probing zinc-immune-cognitive interactions specifically.
- 7Complements the Thymalin coverage on this reference by extending the thymic-peptide family with a defined-nonapeptide research tool.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Subcutaneous / parenteral (research) | Microgram-range doses in preclinical research protocols | Variable across research protocols | Course lengths vary from days to weeks in most research contexts | None cited |
Note: Research protocol standardisation for thymulin specifically is limited; the compound's specialised research applications rather than mainstream research-community usage limit the availability of standardised research protocols.
Section 6
Administration Routes
- Subcutaneous injection in most research contexts.
- Intraperitoneal administration in animal research contexts.
- Intravenous administration in some acute-mechanistic research contexts.
- Oral administration produces limited bioavailability given the nonapeptide structure.
Section 7
Safety Profile
Commonly reported
- · Well-tolerated in preclinical research at studied doses.
- · Injection-site reactions with parenteral administration.
- · Occasional mild transient effects during initial administration.
- · No dependence, tolerance, or withdrawal phenomena documented in the reported research base.
Rare / theoretical
- · Long-term safety data is limited given the compound's specialised research use.
- · Theoretical interactions with immunosuppressive or immunomodulatory pharmaceuticals.
- · Rare hypersensitivity reactions.
- · Zinc-status-dependent activity may complicate research-context interpretation in zinc-deficient contexts.
Contraindications
- · No entry for Thymulin was found in the electronic medicines compendium (emc) on 17 October 2026.
- · Pregnancy and lactation — no controlled data.
- · Active severe autoimmune disease — theoretical contraindication via the immunomodulatory mechanism.
- · Concurrent use with immunosuppressive pharmaceuticals should be evaluated for interaction.
Section 8
UK & EU Regulatory Context
United Kingdom
No entry for Thymulin was found in the electronic medicines compendium (emc) on 17 October 2026. The emc is not a complete record of UK authorisations, so check the MHRA Products database.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
Thymulin foundational characterisation as thymic serum factor
The classical 1970s Bach-laboratory identification and characterisation of thymulin as the thymic serum factor responsible for T-cell maturation effects, establishing the compound's foundational immunological research context and providing the mechanistic scaffold for subsequent research applications.
Thymulin zinc-dependence characterisation
Molecular characterisation of thymulin's zinc-binding requirement for biological activity, distinguishing the zinc-bound active form from the zinc-free inactive form and establishing the distinctive zinc-immune interaction mechanism-of-action framework.
Thymulin in sickness-behaviour research
Research applications of thymulin in sickness-behaviour research contexts, reporting reduced cytokine-mediated cognitive and behavioural effects in lipopolysaccharide-driven sickness models. Provides the immune-cognitive research application angle relevant to inflammation-mediated cognitive decline research.
Thymulin in neuroinflammation and cognitive-ageing research
Preclinical research applications of thymulin in neuroinflammation and cognitive-ageing research contexts, reporting anti-inflammatory effects in CNS injury models and cognitive-endpoint improvements in aged research populations. Extends the immune-cognitive research application angle into cognitive-ageing contexts.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Thymulin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Thymulin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: this page is educational. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying an unauthorised medicinal product, and some compounds on this site, such as semaglutide, are authorised prescription-only medicines in the UK.